Professor, Medicine, UCSD School of Medicine
Cardiology
Dr. Sotirios Tsimikas, MD
|
|
Give Review
Dr. Sotirios Tsimikas is an expert in the field of Cardiology. He researched medicine at University of Massachusetts Medical School. University of Massachusetts Medical School is ranked 49/12 in Research/PrimaryCare. He received awards:"CMS Meaningful Use Stage 1 Certification" and "Fellow (FACC)". Doctor Sotirios Tsimikas, MD is a published doctor as well. He has 45 publications published. The latest was: Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina. He is registered with Medicare and accepts Medicare payments.
Publications
- Plasma Levels of Advanced Glycation End Products Are Related to the Clinical Presentation and Angiographic Severity of Symptomatic Lower Extremity Peripheral Arterial ...
- Retrieval of a detached transseptal sheath tip from a right pulmonary Artery branch following catheter ablation.
- Antisense Inhibition of Apolipoprotein(a) to Lower Plasma Lipoprotein(a) Levels in Humans.
- Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic Myocardial infarction.
- Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society ...
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
- Manganese G8 dendrimers targeted to oxidation-specific epitopes: In vivo MR imaging of atherosclerosis.
- Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies.
- Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprot...
- Lipoprotein Apheresis and Acute Reduction of Arterial Inflammation: FDG-PET as an Imaging Biomarker of Nonpharmacological Effects on the Vessel Wall.
- Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions.
- Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a): Prospective 15-Year Outcomes in the Bruneck Study.
- Release and Capture of Bioactive Oxidized Phospholipids and Oxidized Cholesteryl Esters During Percutaneous Coronary and Peripheral Arterial Interventions in Humans.
- New Therapeutic Targets for Calcific Aortic Valve Stenosis: The Lipoprotein(a)-Lipoprotein-Associated Phospholipase A2-Oxidized Phospholipid Axis.
- Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease.
- Highlights of the Year in JACC 2013.
- Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein (a).
- Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics.
- MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma.
- Determinants of Binding of Oxidized Phospholipids on Apolipoprotein (a) and Lipoprotein (a).
- Tracking oxidatively stressed cardiac stem cells with molecular imaging: "insights" into fate, viability, and function.
- Oxidation-specific biomarkers and risk of peripheral artery Disease.
- Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis.
- Highlights of the Year in JACC 2012.
- Adaptive immunity in atherogenesis: new insights and therapeutic approaches.
- Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events.
- Emerging therapeutic agents to lower lipoprotein (a) levels.
- Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses.
- Advanced glycation end products and diabetic cardiovascular Disease.
- Effect of an oral astaxanthin prodrug (CDX-085) on lipoprotein levels and progression of atherosclerosis in LDLR(-/-) and ApoE(-/-) mice.
- In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity.
- Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following Acute myocardial infarction.
- Lipoprotein oxidation biomarkers for cardiovascular risk: what does the future hold?
- The clinical emergence of optical coherence tomography: defining a role in intravascular imaging.
- Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression.
- Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results fr...
- Molecular imaging of matrix metalloproteinase expression in atherosclerotic plaques of mice deficient in apolipoprotein e or low-density-lipoprotein receptor.
- Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic Syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Br...
- Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel.
- Polyoxygenated Cholesterol Ester Hydroperoxide Activates TLR4 and SYK Dependent Signaling in Macrophages.
- IGHV1-69-Encoded Antibodies Expressed in Chronic Lymphocytic Leukemia React with Malondialdehyde-Acetaldehyde Adduct, an Immunodominant Oxidation-Specific Epitope.
- Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable Angina.
- Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: Phase 2 randomized trial results.
- Population and Assay Thresholds for the Predictive Value of Lipoprotein(a) for Coronary Artery Disease: The EPIC-Norfolk Prospective Population Study.
Schools
University Of Massachusetts Medical School
University Ca San Diego Med Center
University Ma Mem Hlthcare University Campus
Procedures Preformed
- Automatic Implantable Cardioverter Defibrillator (ICD) Implantation
- Cardiac Catheterization (incl. Coronary Angiography)
- Cardiac Imaging
- Cardiac Myocardial Perfusion Imaging
- View All
Conditions Treated
- Aneurysm and Dissection of Heart
- Angina and Acute Coronary Syndrome
- Aortic Aneurysm
- Aortic Valve Disease
- View All
Doctors Specialties
- Cardiology
- Interventional Cardiology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACC)
Education
-
University of California San Diego -
University of Massachusetts -
University of Massachusetts Medical School
Hospital
-
UC San Diego Health
Drug Facts
| NPI NUMBER | 1629124417 | |
| NPPES Provider LastName | TSIMIKAS | |
| NPPES Provider FirstName | SOTIRIOS | |
| NPPES Provider ZIPCode | 920378411 | |
| NPPES Provider State | CA | |
| Specialty Description | Cardiology | |
| Total Claim Count | 495.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629124417 |
| Last Name Of The Provider | TSIMIKAS |
| First Name Of The Provider | SOTIRIOS |
| View All |
Similar Doctors
|
|
Dr. Filip Fattohi, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. C Michael Wright, MD |
|
|
Dr. Douglas W. Triffon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel Blanchard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dennis A. Goodman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Rubenson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marc M. Henis, MD |
|
|
Dr. Malhar P. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erminia M. Guarneri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth Kaback, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Kuzman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kanae Mukai, MD |